Home > Specialists > Pancreatic Surgery > Dr. Liang Liu (刘亮)
Home > Specialists > General Surgery > Dr. Liang Liu (刘亮)
Specialty & Clinical Focus:
Pancreatic surgeon and Director of Pancreatic Surgery at Zhongshan Hospital, Fudan University in Shanghai, with expertise in benign and malignant pancreatic tumors, pancreatic neuroendocrine tumors, lower biliary tract and duodenal tumors, conversion therapy, and complex pancreatic resections.
Professional Title & Qualifications:
Chief Physician
Professor
Dual Doctoral Supervisor (Surgery & Oncology)
Hospital & Department：
Shanghai Zhongshan Hospital, Fudan University – Department of Pancreatic Surgery
(address: No. 180 Fenglin Road, Xuhui District, Shanghai, 200032)
Dr. Liang Liu (刘亮) - Pancreatic Surgeon
Personal Biography
Dr. Liang Liu is a Chief Physician, Professor, and dual doctoral supervisor in Surgery and Oncology, and serves as Director of the Department of Pancreatic Surgery at Zhongshan Hospital, Fudan University in Shanghai. His clinical work covers the surgical diagnosis and treatment of benign and malignant pancreatic tumors, pancreatic neuroendocrine tumors, lower biliary tract and duodenal tumors, and selected complex abdominal tumors, with particular experience in conversion therapy and complex pancreatic resections.
Dr. Liu was a visiting scholar in abdominal surgery and organ transplantation at Freiburg University in Germany from 2005 to 2007. He was first author of the 2012, 2018, and 2020 editions of China’s pancreatic cancer clinical diagnostic standards and comprehensive diagnosis and treatment guidelines. He also serves on national pancreatic cancer and oncology committees and is a member of the American Society of Clinical Oncology and the Japanese Cancer Association.
Why Consult Dr. Liang Liu for Pancreatic Surgery in China?
Dr. Liang Liu is Director of the Department of Pancreatic Surgery at Zhongshan Hospital, Fudan University, and a dual doctoral supervisor in Surgery and Oncology. His role in authoring the 2012, 2018, and 2020 editions of China’s pancreatic cancer clinical standards and comprehensive diagnosis and treatment guidelines reflects sustained involvement in standardized pancreatic cancer care and clinical research.
His clinical focus includes benign and malignant pancreatic tumors, pancreatic neuroendocrine tumors, lower biliary tract and duodenal tumors, retroperitoneal tumors, and complex cases requiring conversion therapy or extensive pancreatic surgery. His experience also includes combined liver-pancreas procedures and pancreatic surgery performed in conjunction with liver transplantation.
For international patients facing a complex pancreatic diagnosis, a remote specialist review can be a practical first step before travel. Organizing diagnostic imaging, pathology reports where available, previous treatment records, and a focused question list allows Dr. Liu to review the case context, explain potential surgical considerations, and identify whether further onsite evaluation in Shanghai should be explored. His work on identifying “non-beneficial surgery” subgroups also reflects a careful, evidence-informed approach to surgical selection rather than intervention without clear clinical rationale.
Pre-Travel Case Review & Specialist Liaison
Before committing to medical travel to Shanghai, MedBridgeNZ coordinates a remote specialist-review pathway with Dr. Liang Liu. We help prepare and organize medical records and diagnostic imaging, coordinate translation where needed, manage secure client-authorized document transfer, and communicate appointment requirements with the relevant specialist office.
Dr. Liu reviews the submitted case materials and provides his independent specialist opinion, recommendations, and responses to the questions included in the case brief. This pre-travel review can clarify potential surgical pathways, including conversion therapy considerations, and identify whether additional onsite testing or evaluation may be needed before travel arrangements are finalized. MedBridgeNZ then supports appointment communication and practical travel-feasibility planning based on the specialist’s feedback.
Disclaimer: MedBridgeNZ is a medical concierge provider serving a global client base. We assist with logistical coordination and facilitate access to healthcare professionals. MedBridgeNZ does not provide medical advice, diagnoses, or treatments.Any clinical feedback, treatment planning or suitability discussion remains with the relevant hospital or licensed specialist.
Secure a Remote Case Review with
Dr. Liang Liu
Areas of Expertise
Comprehensive surgical diagnosis and treatment for benign and malignant pancreatic tumors, pancreatic neuroendocrine tumors, tumors of the lower biliary tract and duodenum, spleen tumors, and retroperitoneal/unknown primary abdominal tumors.
Specializes in large-scale surgeries for "converting unresectable to resectable" cases following conversion therapy.
Specializes in extra-large-scale surgeries such as "combined liver-pancreas resection."
Performed China's first "sequential pancreaticoduodenectomy after in-situ liver transplantation" (2022).
Performed the world's first "simultaneous in-situ liver transplantation combined with total pancreatectomy" (2023).
Performed Zhongshan Hospital's first "in-situ liver transplantation sequential subtotal pancreatectomy after five previous abdominal surgeries" (2024).
Verified Client Satisfaction Metrics
⭐⭐⭐⭐⭐ 5.0/5.0 Overall Rating
* Treatment Pathway Satisfaction:
5.0/5.0
* Communication & Professionalism:
5.0/5.0
* High demand: Chosen online for specialist liaison and case reviews by over:
4,400 clients
(Source: These third-party platform indicators are provided for general reference only. They may change over time and should not be interpreted as a guarantee of diagnosis, treatment suitability, appointment availability, or individual clinical outcome.)
Work Experience
Director, Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University (2022-Present)
Visiting Scholar (Abdominal Surgery and Organ Transplantation), Freiburg University, Germany (Jan 2005 - Jan 2007)
Education & Training
Awards & Honors
"Asian Young Scientist Award" (2010), Japanese Cancer Association
"Tang Zhaoyou-CCB Fund" First Prize (2010, 2011)
"Outstanding Medical Talent" (2015), Shanghai "Medical Elite Star" Program
Cover Figure (2015), World Chinese Journal of Digestology
PCCA-CSPAC-Celgene Fund Outstanding Physician of the Year Award (2016)
First Prize, Shanghai Innovation Achievement Award (2019) (As main contributor)
First Prize, Shanghai Medical Science and Technology Award (2020) (As main contributor)
First Prize, China Anti-Cancer Association Science and Technology Progress Award (2020) (As main contributor)
"Shanghai Outstanding Academic Leader" (2023)
"Famous Doctor of China" (6th Edition) (2023)
"Oriental Talent" (Top-notch Project) (2024)
Academic & Professional Memberships
Member, American Society of Clinical Oncology (ASCO)
Member, Japanese Cancer Association (JCA)
Expert, "Precision Medicine Development Strategy Research" Project Group, Chinese Academy of Sciences & National Natural Science Foundation of China
Expert, "National Large-scale Science Project" Pancreatic Cancer Project Group
Committee Member, Pancreatic Cancer Quality Control Expert Committee, National Cancer Center
Deputy Group Leader, Clinical Research Working Group, Surgical Branch, Chinese Medical Doctor Association
Deputy Group Leader, Neuroendocrine Oncology Group, Oncology Branch, Chinese Medical Doctor Association
Committee Member, Pancreatic Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Committee Member, Neuroendocrine Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Standing Committee Member, Peritoneal Oncology Professional Committee, China Anti-Cancer Association (CACA)
Standing Committee Member, Pancreatic Tumor Professional Committee, International Hepato-Pancreato-Biliary Association (IHPBA), China Branch
Member, Pancreatic Group, General Surgery Branch, Shanghai Medical Association
Research & Publications
Published 93 SCI papers as first or corresponding author in international surgery or oncology journals (including 25 papers with IF > 10).
Principal Investigator for numerous national-level projects, including: 6 NSFC General Program grants, 1 NSFC Major Research Instrument Development project, 1 NSFC International Cooperation & Exchange project, the National Cancer Center "Climbing" Fund, the National Key R&D Program, and the Ministry of Education's Doctoral Program Special Research Fund.
Research findings have been featured in major media outlets such as Wen Wei Po, Jiefang Daily, Guangming Daily, and Reference News.
Co-authored (as deputy chief editor) the first academic monograph of the Shanghai Pancreatic Tumor Institute: "Diagnosis and Treatment of Pancreatic Cancer - New Technologies, New Concepts, New Strategies."
Selected Peer-Reviewed Publications
Yin L, et al. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. J Clin Oncol. 2025;43(26):2863–2874. PMID: 40311105.
Li JA, et al. In Situ Anterior Approach to Dissect the Superior Mesenteric Artery in Minimally Invasive Pancreaticoduodenectomy: Step-by-Step Technique and Video. Ann Surg Oncol. 2026;33(6):5100–5101. PMID: 41575644.
Lin Y, et al. Pancreatic STAT5 Activation Promotes Kras(G12D)-Induced and Inflammation-Induced Acinar-to-Ductal Metaplasia and Pancreatic Cancer. Gut. 2024;73(11):1831–1843. PMID: 38955401.
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.
Frequently Asked Questions (FAQs)
Does Dr. Liu’s expertise match my pancreatic diagnosis?
Dr. Liu’s clinical focus includes benign and malignant pancreatic tumors, pancreatic neuroendocrine tumors, lower biliary tract and duodenal tumors, and selected complex abdominal tumors. For cases currently considered unresectable, his experience with conversion therapy and complex pancreatic resections may be particularly relevant. MedBridgeNZ organizes your medical records, diagnostic imaging, treatment history, and questions, coordinates translation and client-authorized document transfer, and arranges the remote specialist-review process. Dr. Liu then reviews the submitted materials and provides his independent opinion on whether his expertise and potential surgical approaches are relevant to the case.
How can I request a remote specialist review with Dr. Liu from overseas?
To request a remote specialist review from overseas, send MedBridgeNZ your available medical records, diagnostic imaging, prior treatment information, and the questions you want addressed. We coordinate record preparation, translation where needed, secure client-authorized document transfer, appointment communication, and scheduling with Dr. Liu’s specialist office. Dr. Liu reviews the submitted case materials and provides an independent specialist opinion and responses to the questions included in the case brief. Appointment timing is confirmed through the relevant specialist office before the review proceeds.
If Dr. Liu recommends an onsite evaluation or surgery, how can I plan my visit to Shanghai?
If Dr. Liu recommends an onsite evaluation or surgical pathway in Shanghai, MedBridgeNZ can coordinate the non-clinical arrangements for your visit. Support can include medical invitation or visa-document coordination, appointment communication with Zhongshan Hospital, travel and accommodation planning, medical-record translation coordination, and bilingual administrative assistance during hospital visits. We help keep the itinerary, documents, and hospital communication organized so you understand the practical steps before departure, and we can coordinate follow-up appointment communication after the hospital confirms the next steps.
Can Dr. Liu provide a definitive treatment plan through the remote review?
A remote review can provide a substantive specialist opinion based on the medical records and diagnostic imaging you submit. Dr. Liu can outline potential surgical strategies, discuss conversion therapy considerations where relevant, answer the questions included in your case brief, and identify additional tests or onsite evaluation that may be needed. A final treatment plan may still depend on an in-person examination, updated testing, and the hospital’s formal assessment in Shanghai. MedBridgeNZ coordinates the records, translation, document transfer, and appointment communication so the specialist’s feedback is presented clearly before travel planning begins.
Flexible Ways to Connect with the Specialist
We understand that every client’s situation is unique. Beyond the Remote Written Review, we offer a range of flexible ways to access specialist insights:
-
Remote Video Liaison: For a more personal interaction, we can arrange a live video session, allowing you to discuss your case directly with the specialist with the help of our professional medical translators.
-
On-Site Proxy Liaison: If you cannot travel, our dedicated bilingual team can visit the hospital in person on your behalf. We will present your translated medical records to the specialist, facilitate your inquiries, and provide you with a comprehensive translated report of the doctor’s findings.
-
In-Person Appointment Booking: If you are planning to travel to China for treatment, we manage the complex hospital registration and appointment process, ensuring you have confirmed access to your chosen specialist upon arrival.
How MedBridgeNZ Helps You:
MedBridgeNZ is a New Zealand-based medical concierge and logistics coordination provider for international patients exploring specialist-care pathways in China. We coordinate appointment requests, medical-record preparation, translation, secure client-authorized document transfer, medical invitation or visa-document support, travel planning, and non-clinical bilingual administrative assistance for hospital visits. We do not provide medical advice, diagnosis, or treatment; all clinical opinions and treatment decisions are made independently by licensed specialists and hospitals. Our role is to keep the administrative pathway clear and organized, while third-party medical and travel costs remain separate unless expressly stated in writing.